April 23, 2014 — Researchers in Zurich, Switzerland, have successfully used focused ultrasound for the first time to noninvasively ablate part of a recurrent glioma tumor through a patient’s intact skull. The procedure was performed to assess the feasibility and safety of focused ultrasound in treating brain tumors; it was not intended to demonstrate efficacy. The procedure was conducted using InSightec's Exablate Neuro system.

Focused ultrasound employs thousands of ultrasound beams that converge on a spot deep in the body. At this focal point, the ultrasound can cause a variety of biological effects — in this case, heat and destroy the cancerous tissue.

The treatment was conducted at the Focused Ultrasound Center of University Children's Hospital Zurich by a team led by Javier Fandino, M.D., professor of neurosurgery at Kantonsspital Aarau, Switzerland, and Ernst Martin, M.D., professor of neuroradiology, University Children’s Hospital Zurich.

"The patient was awake and responsive during the treatment, and we were able to successfully target and destroy a part of the tumor located deep within the patient's brain,” said Fandino. “We are very encouraged that we could utilize focused ultrasound to accomplish this with no side effects or complications."

"The ability of focused ultrasound to accomplish both small lesions for functional neurosurgery as well as bulk lesions for tumor ablation is amazing," added Martin.

There is an urgent need for new approaches to treating brain tumors. With its ability to noninvasively and accurately target and destroy diseased areas while sparing healthy adjacent brain tissue, focused ultrasound could prove to be a breakthrough.

“Treatment of this patient is the first critical step in the path to developing a new, noninvasive approach for patients with brain tumors that could serve as an alternative to surgery or radiation therapy,” said Neal F. Kassell, M.D., chairman of the Focused Ultrasound Foundation. “Additional clinical trials to prove safety and efficacy are required to translate this milestone into a treatment that could improve the quality of life and longevity for countless individuals.”

Focused ultrasound is an early-stage therapeutic technology with the potential to transform the treatment of many serious medical disorders. This technology uses ultrasonic energy guided by magnetic resonance (MR) or ultrasound imaging to treat tissue deep in the body without incisions or radiation. Multiple intersecting beams of ultrasound are directed and concentrated on a target as small as a grain of rice. The Focused Ultrasound Foundation was created to accelerate the development and adoption of focused ultrasound therapies.

For more information: www.fusfoundation.org


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Feature | Kyle Hardner

Radiotherapy contributes to about 40% of all cancer cures but still lags behind systemic therapy in funding and ...

Time October 21, 2025
arrow
Subscribe Now